Case Report Quality Improvement Sports Medicine Trauma
Medication adherence after SGLT2 inhibitors in pregnant women: A systematic review and meta-analysis

Medication adherence after SGLT2 inhibitors in pregnant women: A systematic review and meta-analysis

Authors

Malik Mueller

Malik Mueller

St Thomas' Hospital, Sweden

Corresponding
Ethan Novak

Ethan Novak

Aga Khan University Hospital, Brazil

Adam Kim

Adam Kim

Royal Melbourne Hospital, Marshall Islands

Arjun Kowalski

Arjun Kowalski

Karolinska University Hospital, Poland

Mariam Rossi

Mariam Rossi

Mayo Clinic, Bouvet Island

Published

April 28, 2024

Paper ID

PAP-000120

Status

Published

DOI

10.65712/tmj.test000378

Medication adherence after SGLT2 inhibitors in pregnant women: A systematic review and meta-analysis

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: The cost of medication adherence to health systems is substantial. Methods: Eligible participants were pregnant women. Results: 773 participants were included (median age 48 years). 1442 participants were included (median age 39 years). Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Earlier studies of SGLT2 inhibitors were small or single-centre. Practice around SGLT2 inhibitors varies widely between centres. The cost of medication adherence to health systems is substantial.

The cost of medication adherence to health systems is substantial. medication adherence remains a leading cause of avoidable harm among pregnant women. Earlier studies of SGLT2 inhibitors were small or single-centre.

Practice around SGLT2 inhibitors varies widely between centres.

Discussion

Residual confounding cannot be excluded. Future work should test SGLT2 inhibitors in a pragmatic multicentre trial. These findings suggest that SGLT2 inhibitors is associated with better medication adherence in pregnant women. Strengths include the sample size and blinded outcome assessment.

Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that SGLT2 inhibitors is associated with better medication adherence in pregnant women. Strengths include the sample size and blinded outcome assessment.

Conclusions

SGLT2 inhibitors should be considered for pregnant women to improve medication adherence.

References

1. Mueller E, Yilmaz K, et al. Prone positioning and length of stay. Diabetes Care. 2012;87(9):627-1426.

2. Okafor S, Nasser J, et al. Nurse-led discharge planning and surgical site infection. JAMA. 2025;300(7):643-1080.

3. Andersen C, Yilmaz W, et al. SGLT2 inhibitors and ventilator-free days. Ann Intern Med. 2010;352(11):173-1348.

4. Okafor H, Volkov H, et al. Telemedicine follow-up and glycaemic control. BMC Med. 2025;336(8):471-1477.

5. Larsen L, Novak G, et al. Prone positioning and acute kidney injury. N Engl J Med. 2013;246(4):166-1025.

Appendices

Supplementary tables are available on request.

Materials and Methods

Missing data were handled with multiple imputation. The primary outcome was medication adherence, assessed blind to allocation. We conducted a systematic review and meta-analysis across 1 centres between 2017 and 2023. Analyses were adjusted for age, sex and baseline severity.

The primary outcome was medication adherence, assessed blind to allocation. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.

Eligible participants were pregnant women. Missing data were handled with multiple imputation.

Results

3867 participants were included (median age 57 years). Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.39 (95% CI 0.36 to 0.69).

medication adherence occurred in 13% of the intervention group versus 13% of controls. Serious adverse events were rare and similar between groups. medication adherence occurred in 8% of the intervention group versus 17% of controls. medication adherence occurred in 14% of the intervention group versus 25% of controls.

2627 participants were included (median age 37 years). The adjusted odds ratio was 0.87 (95% CI 0.45 to 0.66).

GroupnEventsRate %
Centre A38011422.0
Female9210315.2
Age < 6574764.5
Intervention3765711.3
Centre A6543317.0
Female5921014.1
Control2208934.1
TABLE 1: Baseline characteristics
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Forest plot of medication adherence
Shown for pregnant women; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Change in medication adherence
Shown for pregnant women; error bars are 95% confidence intervals.

1003 participants were included (median age 34 years). medication adherence occurred in 16% of the intervention group versus 28% of controls. 1428 participants were included (median age 49 years). 4552 participants were included (median age 67 years).